Eye Catching Stock News: Surmodics, Inc. (NASDAQ: SRDX)

On 21 Nov 2019, Surmodics, Inc. (NASDAQ: SRDX) stock observed trading -35.42% off 52-week high price. On the other end, the stock has been noted 4.73% away from low price over the last 52-weeks. The stock disclosed a move of -8.59% away from 50 day moving average and -10.40% away from 200 day moving average. Moving closer, we can see that shares have been trading -4.24% off 20-day moving average. It has market cap of $532.53M.

Surmodics, Inc. (SRDX) recently reported results for its fiscal 2019 fourth quarter ended September 30, 2019, and provided its financial outlook for fiscal 2020.

Fourth Quarter Fiscal 2019 Financial Results

Total revenue for the fourth quarter of fiscal 2019 was $30.8M, as contrast with $23.0M in the prior-year period. Medical Device revenue was $24.8M in the fourth quarter of fiscal 2019, as contrast with $17.0M in the year-before period, a raise of 46%. Revenue in the fourth quarter includes $7.6M from our SurVeil contract with Abbott, as contrast with $2.2M in the prior-year quarter. In Vitro Diagnostics revenue was $6.0M for the fourth quarter of fiscal 2019 as contrast with $6.1M in the same prior-year quarter, a decrease of 1%.

Diluted GAAP earnings per share in the fourth quarter of fiscal 2019 were $0.26 as contrast with a loss per share of $(0.13) in the year-before period. On a non-GAAP basis, earnings per share were $0.37 in the fourth quarter of fiscal 2019, as contrast with $0.05 in the year-before period.

As of September 30, 2019, cash and investments were $55.3M. Surmodics generated $12.5M of cash from operating activities in the fourth quarter of fiscal 2019. Capital expenditures totaled $1.9M for the fourth quarter of fiscal 2019.

Fiscal 2020 Guidance

Surmodics expects fiscal year 2020 revenue to range from $87M to $91M. The Company expects diluted EPS in the range of ($0.60) to ($0.30) per share, which reflects the Company’s continued investment to advance its whole-product solutions strategy. Non-GAAP diluted EPS is predictable to be in the range of ($0.44) to ($0.14) per share.

The USA based company Surmodics, Inc. moved with change of -0.20% to $39.86 with the total traded volume of 76024 shares in recent session versus to an average volume of 86.56K. The stock was observed in the 5 days activity at 1.32%. The one-month performance of stock was -10.53%. SRDX’s shares are at -6.61% for the quarter and driving a -27.86% return over the course of the past year and is now at -15.66% since this point in 2018.  Right now, the stock beta is 1.02. The average volatility for the week and month was at 2.32% and 3.47% respectively. There are 13.36M shares outstanding and 13.08M shares are floated in market.

 

Leave a Reply

Your email address will not be published. Required fields are marked *